Celltrion set to build largest biopharma plant in China

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/W D Stuart)
(Image: Getty/W D Stuart)

Related tags: Celltrion, South korea, China, Infliximab

The South Korean company plans to invest ₩600bn over a five-year period to support the construction of its first facility in China.

According to local media reports​, Celltrion announced that it would build the new facility in Wuhan, China, to produce both its own products and contract manufacturing organization (CMO) projects.

The ₩600bn ($520m) plant will have a capacity of 120,000L, significantly contributing to the company’s stated aim of expanding global production capacity to one million liters​ by 2030.

In a twist, the project to build the facility will also see Celltrion back out of its previously announced deal to create a joint venture with Nan Fung Group​, stated Korea JoongAng Daily.

This would have seen the joint venture, to be known as Vcell Healthcare, hold the rights to three of Celltrion’s biosimilars, as well as having plans to create a ‘world-class biologics manufacturing facility’.

With the most recent announcement, the joint venture has been rendered unnecessary and, instead, Celltrion will establish a local subsidiary in the area, with its own sales network.

The newly-announced facility arrives days after Celltrion stated​, at the J.P. Morgan Healthcare Conference, that it plans to launch one biosimilar product per year through to 2030.

The company pointed to the successful launch of its subcutaneous infliximab biosimilar​, Remsima SC, as a positive sign within its portfolio, as well as Remsima developing a larger share in Europe than the originator product.

Looking to the future, Celltrion also stated that it plans to ‘reach beyond biosimilars’ to expand into drug development.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more